HomeNewsBusinessReal EstateCOVID-19 impact: Office leasing dips by 38%; at 10.9 mn sq ft across top six cities

COVID-19 impact: Office leasing dips by 38%; at 10.9 mn sq ft across top six cities

Bengaluru, Delhi NCR and Mumbai constituted around 69% of the total leasing activity in H1 2021 across top cities of the country

July 20, 2021 / 12:53 IST
Story continues below Advertisement

India’s office space leasing market moved at a measured pace as most occupiers halted their expansion plans in the wake of the unanticipated second wave of COVID-19. In the January-June 2021 period, office absorption in six major cities stood at approximately 10.9 mn sq. ft, down 38% from the corresponding months a year ago, Savills India said in a report.

The new supply rose by 4% at 18.0 mn sq. ft. in H1 2021 from the year-ago period, Savills India said in the report titled India Market Watch Office.

Story continues below Advertisement

Despite the ongoing pandemic, the technology (IT) occupiers continue to lead the demand followed by the BFSI segment. While the IT sector has increased absorption and holds a 51% of the share, their combined share of approximately 63% is the same as in H1 2020, it said.

Bengaluru, Delhi NCR and Mumbai constituted around 69% of the total leasing activity in H1 2021 across top cities of the country. Bengaluru continued to lead with 4.1 mn sq.ft of leasing activity representing 37% share in H1 2021 followed by Delhi NCR which witnessed leasing activity of 2.0 mn sq.ft. recording a 37% YOY decline, the report said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show